Rhythm Pharmaceuticals, Inc. Common Stock Earnings Dividend

Rhythm Pharmaceuticals, Inc. Common Stock’s revenue jumped 46.91% since last year same period to $71.26Mn in the Q2 2026. On a quarterly growth basis, Rhythm Pharmaceuticals, Inc. Common Stock has generated 18.54% jump in its revenue since last 3-months.

Rhythm Pharmaceuticals, Inc. Common Stock’s net profit fell -5.72% since last year same period to $-49.3Mn in the Q2 2026. On a quarterly growth basis, Rhythm Pharmaceuticals, Inc. Common Stock has generated 11.4% jump in its net profits since last 3-months.

Rhythm Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 28.04% since last year same period to -69.19% in the Q2 2026. On a quarterly growth basis, Rhythm Pharmaceuticals, Inc. Common Stock has generated 25.25% jump in its net profit margins since last 3-months.

Rhythm Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a 5.81% jump from last quarter’s estimates.

Rhythm Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.81.

Rhythm Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 2.67% since last year same period to -0.73 in the Q2 2026. This indicates that the Rhythm Pharmaceuticals, Inc. Common Stock has generated 2.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.